First Citizens Bank & Trust Co. Raises Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

First Citizens Bank & Trust Co. increased its position in Becton, Dickinson and Company (NYSE:BDXFree Report) by 37.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,197 shares of the medical instruments supplier’s stock after purchasing an additional 325 shares during the period. First Citizens Bank & Trust Co.’s holdings in Becton, Dickinson and Company were worth $292,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fairfield Bush & CO. bought a new stake in Becton, Dickinson and Company in the first quarter worth $114,000. Sequoia Financial Advisors LLC boosted its holdings in Becton, Dickinson and Company by 11.3% in the first quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier’s stock worth $778,000 after acquiring an additional 297 shares in the last quarter. Brighton Jones LLC boosted its holdings in Becton, Dickinson and Company by 8.8% in the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $368,000 after acquiring an additional 112 shares in the last quarter. Zions Bancorporation N.A. boosted its holdings in Becton, Dickinson and Company by 13.0% in the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier’s stock worth $134,000 after acquiring an additional 58 shares in the last quarter. Finally, Mather Group LLC. boosted its holdings in Becton, Dickinson and Company by 26.0% in the first quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier’s stock worth $358,000 after acquiring an additional 278 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Up 1.1 %

BDX stock opened at $243.72 on Thursday. Becton, Dickinson and Company has a fifty-two week low of $229.85 and a fifty-two week high of $287.32. The business’s 50-day moving average is $240.08 and its two-hundred day moving average is $244.35. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The company has a market cap of $70.41 billion, a price-to-earnings ratio of 57.75, a P/E/G ratio of 2.02 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last issued its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.98 earnings per share. As a group, analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were given a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 1.56%. The ex-dividend date was Thursday, March 7th. Becton, Dickinson and Company’s payout ratio is 90.05%.

Analysts Set New Price Targets

Several research firms have commented on BDX. Barclays boosted their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Raymond James increased their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $279.17.

Get Our Latest Stock Report on Becton, Dickinson and Company

Insiders Place Their Bets

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

See Also

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.